ADMA Biologics Inc (ADMA) Stock Rises on Q4 2025 Earnings

ADMA Biologics Inc (ADMA) reported fourth-quarter 2025 results showing mixed performance: revenue and operating margins expanded while bottom-line metrics weakened year over year.

Revenue rose 18.4% year-over-year to $139.2 million.

Gross profit increased 40.2% to $88.8 million.

Operating profit grew 63.7% to $62.8 million.

Net income attributable to common shareholders declined 55.9% to $49.4 million, and diluted earnings per share fell 56.5% to $0.20.

Against analyst expectations, revenue came in below the forecast of $142.2 million, while reported diluted EPS of $0.20 modestly exceeded the estimate of $0.19. The stock moved about 2.61% since market close.

Cash from operating activities dropped 73.5% to $13.3 million.

Capital expenditures (purchases of property, plant and equipment) increased sharply to $14.4 million (a 421.1% rise year-over-year).

Cash and cash equivalents were $87.6 million, down 15.0% year-over-year.

Cost of sales was $50.3 million, down 7.1% year-over-year.

Total liabilities stood at $146.9 million, up 5.2% year-over-year.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

ADMA Biologics Inc Insider Trading Activity

ADMA Biologics Inc insiders have traded $ADMA stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $ADMA stock by insiders over the last 6 months:

ADAM S GROSSMAN (President and CEO) has made 0 purchases and 10 sales selling 105,000 shares for an estimated $1,764,000.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

ADMA Biologics Inc Hedge Fund Activity

We have seen 189 institutional investors add shares of ADMA Biologics Inc stock to their portfolio, and 246 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC added 3,838,158 shares (+3906.1%) to their portfolio in Q4 2025, for an estimated $70,008,001
CAPITAL RESEARCH GLOBAL INVESTORS added 3,383,559 shares (+104.0%) to their portfolio in Q4 2025, for an estimated $61,716,116
OBERWEIS ASSET MANAGEMENT INC/ removed 2,712,040 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $49,467,609
UBS GROUP AG added 2,581,670 shares (+129.9%) to their portfolio in Q4 2025, for an estimated $47,089,660
DRIEHAUS CAPITAL MANAGEMENT LLC removed 2,477,013 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $36,313,010
SACHEM HEAD CAPITAL MANAGEMENT LP added 2,415,000 shares (+27.0%) to their portfolio in Q4 2025, for an estimated $44,049,599
PERPETUAL LTD removed 2,119,291 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $38,655,867

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.